Breast Cancer Research and Treatment **41**: 297, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 41

(not including abstracts)

Abbattista A 177
Andersen TI 103
Anderson E 31
Andreotti PE 161
Andrieu C 141
Archer P 1
Ausch C 171

Barbieri Neto J 95
Bast RC 1
Bécette V 141
Bell NH 71
Bitter MA 1
Blamey RW 31
Bonadonna G 177
Børresen A-L 103
Bouchet-Bernet C 141
Brenne U 161
Bruckner HW 161

Campani D 43
Casartelli C 95
Chevillard S 81
Chitemerere M 103
Clarke R 31
Claudio JA 111
Cree IA 161
Cullen KJ 43
Czerwenka K 51

Daly MB 59
Demicheli R 177
Deytieux S 141
Dowsett M 31

Eaves CJ 147
Emerman JT 111,147
Evans GL 71

Formento J-L 131
Franklin WA 1

Garza-Williams S 1
Gee JMW 31
Giani C 43
Goussard J 131
Greco RS 15

Hami L 1
Hauck ER 71
Hertz-Picciotto I 21
Heuss F 51
Holm R 103
Hosmann JW 51
Howell A 31

Jelincic D 51
Johnston CS 1
Jones RB 1

Karlsen F 103
Krebs D 161
Kubista E 51
Kurbacher CM 161
Kurbacher JA 161

Lainé-Bidron C 81
Lerman CL 59
Levalois C 81
Lu Y 51

Mæhle BO 123
Magdelénat H 81,131
Mallmann P 161
Manavi M 51
Manning DL 31
Masny A 59
McClelland RA 31
Meyer deP Philbert P 95
Miceli R 177
Moroz C 171
Müller A 81

Nesland JM 103
Nicholson RI 31

Oglobine J 141

Petersen A 147

Rasmussen A 43
Reiner G 171
Reinerova M 171
Robertson JFR 31
Rodríguez Burbano R 95
Romain S 131
Rosen HR 171
Ross E 59

Sands CB 59
Schiessel R 171
Schildkraut JM 21
Schwartz MD 59
Shpall EJ 1,147
Sibonga JD 71
Spyratos F 131,141
Sting J 147
Suris-Swartz PJ 21
Svec J 171

Tretli S 123
Tüchler H 171
Turner RT 71

Valagussa P 177
Vielh Ph 81
Vine MF 21

Wakeling AE 31
Wapnir IL 15
Wartenberg DE 15

Breast Cancer Research and Treatment **41**: 299–303, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 41

adjuvant chemotherapy
survey of American women (abstract) 221
adjuvant therapy
abstracts 234-235
adriamycin
resistance reversal by cyclosporin A and MPA, not tamoxifen 111-122
age at diagnosis
primary breast cancer before 50 and 4x risk of ovarian cancer 21-29
angiogenesis
abstracts 243-244
antiestrogens
abstracts 244-245
apoptosis induction without bcl-2 change (abstract) 225
ICI 182,780 reduces ER protein, not mRNA 31-41
tamoxifen and bone loss, pre and post menopausal rat model 71-79
antigens
abstracts 298
apoptosis
abstracts 282-283
ATP bioluminescence assay
for chemosensitivity to mitoxantrone, doxorubicin 161-170
autologous stem cell support
see bone marrow transplantation
axillary nodes
abstracts 275-277

benign breast disease
cystic disease and risk of breast cancer (abstract) 227
cytogenetic analysis of 5 mammary hyperplasias 95-101
see also premalignant disease
blood
detection of tumor cells — abstracts 230-231
bone loss
estrogen protection partially antagonized by tamoxifen in premenopausal rat model 71-79
bone marrow
detection of tumor cells — abstracts 230-231
prognostic impact of micrometastatic tumor cells (abstract) 223
bone marrow metastatic infiltrates
selective growth of breast epithelial cells 147-159
bone marrow transplantation
immunocytochemical detection of cancer cells in marrow and blood 1-13
bone metastasis
TGFβ blockade decreases osteolysis (abstract) 222
BRCA1
abstracts 270-271
breast conservation
abstracts 235-236
medical contraindications and underutilization (abstract) 223
skin recurrences (abstract) 223

carcinogenesis
abstracts 298
chemosensitivity assays
microplate ATP bioluminescence assay, mitoxantrone vs. doxorubicin 161-170
chemotherapy
abstracts 236-238
CMFVP vs. melphalan — 20 year results (abstract) 221
new drugs and formulations, abstracts 287-290
see also adjuvant chemotherapy, neoadjuvant chemotherapy
chemotherapy, dose-intense
abstracts 277-280
recombinant IL-11 reduces platelet transfusions (abstract) 224
constant denaturant gel electrophoresis
in detection of p53 mutations in DCIS 103-109
cost-effectiveness
abstracts 259-260
cyclosporin A
adriamycin resistance suppression in primary cultures 111-122

cytogenetics
in mammary epithelial hyperplasias, 5 cases 95-101
cytokeratins
and selective growth of epithelial cells from bone marrow 147-159

DCIS
abstracts 240-241
allelic loss and genetic progression (abstract) 226
histological grading (abstract) 223
natural suppression by myoepithelial cells? (abstract) 226
p53 mutations (vs. atypical ductal hyperplasias) 103-109
detection
tumor cells in marrow and blood – abstracts 230-231
diagnosis
abstracts 231-232
diet
abstracts 265
doxorubicin
chemosensitivity assay, vs. mitoxantrone 161-170
drug resistance
abstracts 242-243
chemosensitivity assays – no cross-resistance between mitoxantrone and doxorubicin in many patients 161-170
P-glycoprotein in primary cultures after previous chemotherapy 111-122
suppression by cyclosporin A and MPA, not tamoxifen 111-122
ductal carcinoma in situ
see DCIS

endocrine therapy
abstracts 290-293
letrozole vs. megestrol acetate (abstract) 222
endocrinology
abstracts 267-268
epidemiology
abstracts 263
epithelial cells
breast – selective growth from bone marrow 147-159

erbB-2
strong signal in mammary Paget cells 51-57
estrogen receptor
abstracts 245-246
EORTC quality control — ligand binding and EIA 131-139
ICI 182,780 reduces ER protein, not mRNA 31-41
in benign epithelium – breast cancer risk (abstract) 227
reverses effect of obesity on prognosis 123-130
RT-PCR vs. EIA assays 81-89
estrogen replacement therapy
and risk of fatal breast cancer (abstract) 221

familial breast cancer
abstracts 262-263
familial cancer
primary breast cancer before 50 and 4x risk of ovarian cancer 21-29

Gail model risk components
unrelated to individual perception of risk 59-70
genetics
primary breast cancer before 50 and 4x risk of ovarian cancer 21-29
growth factors and inhibitors
abstracts 296-297

HER-2/*neu*
see erbB-2
hereditary breast cancer
abstracts 262-263
human papilloma virus (HPV)
DNA absent in mammary Paget's disease 51-57
hyperplasia
atypical — no p53 alterations (cf. DCIS) 103-109
cytogenetic analysis of 5 cases 95-101

IGF binding proteins
new related gene T1A12 – reduced expression with progression (abstract) 225
IGF-II
mRNA and protein in the stroma of invasive breast cancers 43-50
imaging
abstracts 228-230

immunology and immunotherapy
abstracts 247-249
immunosuppression
by breast cancer related antigen p43 171-176
immunotherapy
engineered tumor vaccines and peptide-pulsed dendritic cells (abstract) 224
insulin-like growth factors
see IGFs
invasion and metastasis
abstracts 283-286

lobular carcinoma in situ (LCIS)
and risk of local recurrence (abstract) 226
lymphocytes
from breast cancer patients vs. normals — immunosuppression by p43 antigen 171-176

magnetic resonance imaging (MRI)
tumor anatomy and angiogenesis (abstract) 224
male breast cancer
diagnosis — abstract 233
malignant progression
p53 mutations in DCIS, not atypical hyperplasia 103-109
mammary Paget's disease
HPV DNA absent, erbB-2 present 51-57
mammography
abstracts 228-230
mammography behavior
risk perception unrelated to Gail model risk components 59-70
markers
in serum — abstracts 233-234
marrow progenitor cells
CD-34 purging 1-13
medroxyprogesterone acetate (MPA)
adriamycin resistance suppression in primary cultures 111-122
metastasis
abstracts 283-286
multipeak time distribution after mastectomy — implications for dormancy 177-185
mitoxantrone
chemosensitivity assay, vs. doxorubicin 161-170
monoclonal antibodies
immunocytochemical detection of cancer cells in marrow and blood 1-13

multidrug resistance
see drug resistance

neoadjuvant chemotherapy
abstracts 293-295
nipples
HPV DNA absent, erbB-2 present in Paget's disease 51-57
nutrition
abstracts 265

obesity
opposite survival effects depending on hormone receptor status 123-130
oncogenes
abstracts 270-272
ovarian cancer
primary breast cancer before 50 and 4x risk of ovarian cancer 21-29

P-glycoprotein
in primary cultures after previous chemotherapy 111-122
p43 breast cancer associated antigen
immunosuppressive properties on patient vs. normal lymphocytes 171-176
p53
mutations in DCIS, not atypical hyperplasia 103-109
Paget's disease
HPV DNA absent, erbB-2 present 51-57
PAI-2 (plasminogen activator inhibitor-2)
extraction conditions for ELISA assay 141-146
papilloma virus (HPV)
DNA absent in mammary Paget's disease 51-57
paracrine interactions
IGF-II mRNA and protein in the stroma of invasive breast cancers 43-50
patient management
abstracts 260-261
pharmacology
abstracts 259
polymerase chain reaction
RT-PCR vs. EIA assays for estrogen and progesterone receptors 81-89
practice guidelines
variations in a comprehensive cancer center (abstract) 224

premalignant disease
genetic aberrations by CGH (abstract) 225
molecular alterations – implications for prevention (abstract) 225
proliferation and apoptosis in normal vs. premalignant breast (abstract) 226
see also benign breast disease
prevention
abstracts 266-267
risk perception unrelated to Gail model risk components 59-70
primary cultures
in tests of multidrug resistance modifiers 111-122
progesterone receptor
abstract 247
EORTC quality control — ligand binding and EIA 131-139
reverses effect of obesity on prognosis 123-130
RT-PCR vs. EIA assays 81-89
prognostic factors
abstracts 250-257
ellipsoidal vs. spherical tumor size calculations 15-19
extraction conditions for uPAR and PAI-2 assays 141-146
opposite obesity effects depending on hormone receptor status 123-130
pS2
mRNA reduced by ICI 182,780, not tamoxifen 31-41
psychosocial aspects
abstracts 296
risk perception unrelated to Gail model risk components 59-70

quality control
ligand binding and EIA for ER and PgR — EORTC 131-139
Quetelet's index
see obesity

racial aspects
abstracts 264
radiation therapy
abstracts 257-258
delay for adjuvant chemotherapy and recurrence (abstract) 221
recurrence risk after mastectomy
multipeak time distribution, implications for dormancy 177-185
retinoids
chemoprevention by an RXR selective ligand (abstract) 222
risk factors
abstracts 264-265
body size and physical activity (abstract) 227
primary breast cancer before 50 and 4x risk of ovarian cancer 21-29
risk perception unrelated to Gail model risk components 59-70

screening behavior
risk perception unrelated to Gail model risk components 59-70
serum markers
abstracts 233-234
smooth muscle
IGF-II mRNA and protein in the stroma, vessels, and ducts of invasive breast cancers 43-50
staging
ellipsoidal vs. spherical size calculations 15-19
stromal cells
IGF-II mRNA and protein in the stroma of invasive breast cancers 43-50
surgery
abstracts 239-240
see also breast conservation

tamoxifen
and bone loss, pre and post menopausal rat model 71-79
blockade of TGFβ reverses resistance (abstract) 222
ICI 182,780 but not tamoxifen reduces ER protein, not mRNA 31-41
no suppression of adriamycin resistance in primary cultures 111-122
trial design
abstract 242
tumor biology
abstracts 272-274
tumor cell biology
abstracts 268-269

tumor dormancy
multipeak time distribution of recurrence 177-185
tumor evolution
abstracts 280-282
tumor size
ellipsoidal vs. spherical size calculations 15-19
tumor suppressor genes
abstracts 270-272
p53 mutations in DCIS, not atypical hyperplasia 103-109

uPA (urokinase-type plasminogen activator) receptor
extraction conditions for ELISA assay 141-146